Inflammatory mechanisms in atherosclerosis: The impact of matrix metalloproteinases

Current Topics in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1132-1148

  Siasos, Gerasimos ^a   Tousoulis, Dimitris ^a   Kioufis, Stamatios ^a   Oikonomou, Evangelos ^a   Siasou, Zoi ^a   Limperi, Maria ^a   Papavassiliou, Athanasios G ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Cardiac remodeling; Cardiovascular risk factors; Endothelial function; Extra cellular matrix; Inflammation; Matrix metalloproteinases

Indexed keywords

ALDOSTERONE ANTAGONIST; AMLODIPINE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; DIHYDROPYRIDINE; DILTIAZEM; ENDOTHELIN RECEPTOR ANTAGONIST; FLUINDOSTATIN; GLYCERYL TRINITRATE; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; OMEGA 3 FATTY ACID; PHENYLALKYLAMINE; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DOWN REGULATION; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HEART FAILURE; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; PULMONARY HYPERTENSION; UPREGULATION;

EID: 84861159531     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611208011132     Document Type: Article

References (209)

1. www.ehnheart.org (accessed May).
2. Libby, P. Inflammation in atherosclerosis. Nature 2002, 420(6917), 868-874.
3. Trexler, M.; Briknarova, K.; Gehrmann, M.; Llinas, M.; Patthy, L. Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem., 2003, 27814), 12241-12246.
4. Siasos, G.; Tousoulis, D.; Antoniades, C.; Stefanadi, E.; Stefanadis, C. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int. J. Cardiol., 2007, 116(3), 300-308.
5. Siasos, G.; Tousoulis, D.; Siasou, G.; Moschos, M. M.; Oikonomou, E.; Zaromitidou, M.; Marinos, G.; Korompelis, P.; Papavassiliou, A. G.; Stefanadis, C. The association between glaucoma, vascular function and inflammatory process. Int. J. Cardiol., 2011, 146(1), 113-115.
6. Kampoli, A. M.; Tousoulis, D.; Antoniades, C.; Siasos, G.; Stefanadis, C. Biomarkers of premature atherosclerosis. Trends Mol. Med., 2009, 15(7), 323-332.
7. Birkedal-Hansen, H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol., 1995, 7(5), 728-735.
8. McCawley, L. J.; Matrisian, L. M. Matrix metalloproteinases: they're not just for matrix anymore! Curr. Opin. Cell Biol., 2001, 13(5), 534-540.
9. Plutzky, J. The vascular biology of atherosclerosis. Am. J. Med., 2003, 115 Suppl 8A, 55S-61S.
10. Creemers, E. E.; Cleutjens, J. P.; Smits, J. F.; Daemen, M. J. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res., 2001, 89(3), 201-210.
11. Van Wart, H. E.; Birkedal-Hansen, H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA, 1990, 87(14), 5578-5582.
12. Pei, D.; Kang, T.; Qi, H. Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem., 2000, 275(43), 33988-33997.
13. Morgunova, E.; Tuuttila, A.; Bergmann, U.; Isupov, M.; Lindqvist, Y.; Schneider, G.; Tryggvason, K. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science, 1999, 284(5420), 1667-1670.
14. Collier, I. E.; Wilhelm, S. M.; Eisen, A. Z.; Marmer, B. L.; Grant, G. A.; Seltzer, J. L.; Kronberger, A.; He, C. S.; Bauer, E. A.; Goldberg, G. I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J. Biol. Chem., 1988, 263(14), 6579-6587.
15. Chow, A. K.; Cena, J.; Schulz, R., Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br. J. Pharmacol., 2007, 152(2), 189-205.
16. Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.; Tschesche, H.; Chen, J.; Van Wart, H.; Poole, A. R., Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J. Clin. Invest., 1997, 99(7), 1534-1545.
17. Hahn-Dantona, E. A.; Aimes, R. T.; Quigley, J. P. The isolation, characterization, and molecular cloning of a 75-kDa gelatinase Blike enzyme, a member of the matrix metalloproteinase (MMP) family. An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical properties. J. Biol. Chem., 2000, 275(52), 40827-40838.
18. Henney, A. M.; Wakeley, P. R.; Davies, M. J.; Foster, K.; Hembry, R.; Murphy, G.; Humphries, S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA, 1991, 88(18), 8154-8158.
19. Schonbeck, U.; Mach, F.; Sukhova, G. K.; Atkinson, E.; Levesque, E.; Herman, M.; Graber, P.; Basset, P.; Libby, P., Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J. Exp. Med., 1999, 189(5), 843-853.
20. Murphy, G.; Segain, J. P.; O'Shea, M.; Cockett, M.; Ioannou, C.; Lefebvre, O.; Chambon, P.; Basset, P. The 28-kDa N-terminal domain of mouse stromelysin-3 has the general properties of a weak metalloproteinase. J. Biol. Chem., 1993, 268(21), 15435-15441.
21. Lijnen, H. R.; Collen, D., Matrix metalloproteinase system deficiencies and matrix degradation. Thromb Haemost 1999, 82 (2), 837-845.
22. Jormsjo, S.; Ye, S.; Moritz, J.; Walter, D. H.; Dimmeler, S.; Zeiher, A. M.; Henney, A.; Hamsten, A.; Eriksson, P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ. Res., 2000, 86(9), 998-1003.
23. d'Ortho, M. P.; Stanton, H.; Butler, M.; Atkinson, S. J.; Murphy, G.; Hembry, R. M. MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Lett., 1998, 421(2), 159-164.
24. Butler, G. S.; Will, H.; Atkinson, S. J.; Murphy, G. Membranetype-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases. Eur. J. Biochem., 1997, 244(2), 653-657.
25. Shimada, T.; Nakamura, H.; Ohuchi, E.; Fujii, Y.; Murakami, Y.; Sato, H.; Seiki, M.; Okada, Y. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase. Eur. J. Biochem., 1999, 262(3), 907-914.
26. Pace, J. L.; Chai, T. J.; Rossi, H. A.; Jiang, X., Effect of bile on Vibrio parahaemolyticus. Appl. Environ. Microbiol., 1997, 63(6), 2372-2377.
27. Hagemann, C.; Anacker, J.; Haas, S.; Riesner, D.; Schomig, B.; Ernestus, R. I.; Vince, G. H., Comparative expression pattern of Matrix-Metalloproteinases in human glioblastoma cell-lines and primary cultures. BMC Res. Notes 3, 293.
28. Van Lint, P.; Libert, C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 2007, 82(6), 1375-1381.
29. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res., 2003, 92(8), 827-839.
30. Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases. J. Biol. Chem., 1999, 274(31), 21491-21494.
31. Hooper, N. M., Families of zinc metalloproteases. FEBS Lett., 1994, 354(1), 1-6.
32. Garcia-Touchard, A.; Henry, T. D.; Sangiorgi, G.; Spagnoli, L. G.; Mauriello, A.; Conover, C.; Schwartz, R. S. Extracellular proteases in atherosclerosis and restenosis. Arterioscler Thromb. Vasc. Biol., 2005, 25(6), 1119-1127.
33. Sakai, T.; Gross, J. Some properties of the products of reaction of tadpole collagenase with collagen. Biochemistry, 1967, 6(2), 518-528.
34. Welgus, H. G.; Jeffrey, J. J.; Stricklin, G. P.; Eisen, A. Z. The gelatinolytic activity of human skin fibroblast collagenase. J. Biol. Chem., 1982, 257(19), 11534-11539.
35. Sukhova, G. K.; Schonbeck, U.; Rabkin, E.; Schoen, F. J.; Poole, A. R.; Billinghurst, R. C.; Libby, P. Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation, 1999, 99(19), 2503-2509.
36. Galis, Z. S.; Khatri, J. J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90(3), 251-262.
37. Jones, C. B.; Sane, D. C.; Herrington, D. M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc. Res., 2003, 59(4), 812-823.
38. Fabunmi, R. P.; Sukhova, G. K.; Sugiyama, S.; Libby, P. Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells: a potential protective mechanism in plaque stability. Circ. Res., 1998, 83(3), 270-278.
39. Ito, A.; Sato, T.; Iga, T.; Mori, Y. Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblasts. FEBS Lett., 1990, 269(1), 93-95.
40. Mauviel, A. Cytokine regulation of metalloproteinase gene expression. J Cell Biochem., 1993, 53(4), 288-295.
41. Gomez, D. E.; Alonso, D. F.; Yoshiji, H.; Thorgeirsson, U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol., 1997, 74(2), 111-122.
42. Wang, H.; Keiser, J. A. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ. Res., 1998, 83(8), 832-840.
43. Mach, F.; Schonbeck, U.; Bonnefoy, J. Y.; Pober, J. S.; Libby, P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation, 1997, 96(2), 396-399.
44. Kol, A.; Sukhova, G. K.; Lichtman, A. H.; Libby, P. Chlamydial heat shock protein 60 localizes in human atheroma and regulatesmacrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation, 1998, 98(4), 300-307.
45. Duhamel-Clerin, E.; Orvain, C.; Lanza, F.; Cazenave, J. P.; Klein-Soyer, C. Thrombin receptor-mediated increase of two matrix metalloproteinases, MMP-1 and MMP-3, in human endothelial cells. Arterioscler Thromb. Vasc. Biol., 1997, 17(10), 1931-1938.
46. Ben-Yosef, Y.; Lahat, N.; Shapiro, S.; Bitterman, H.; Miller, A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ. Res., 2002, 90(7), 784-791.
47. Feinberg, M. W.; Jain, M. K.; Werner, F.; Sibinga, N. E.; Wiesel, P.; Wang, H.; Topper, J. N.; Perrella, M. A.; Lee, M. E. Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J. Biol. Chem., 2000, 275(33), 25766-25773.
48. Lane, W. J.; Dias, S.; Hattori, K.; Heissig, B.; Choy, M.; Rabbany, S. Y.; Wood, J.; Moore, M. A.; Rafii, S. Stromal-derived factor 1-induced megakaryocyte migration and platelet production is dependent on matrix metalloproteinases. Blood, 2000, 96(13), 4152-4159.
49. Wassenaar, A.; Verschoor, T.; Kievits, F.; Den Hartog, M. T.; Kapsenberg, M. L.; Everts, V.; Snijders, A. CD40 engagement modulates the production of matrix metalloproteinases by gingival fibroblasts. Clin. Exp. Immunol., 1999, 115(1), 161-167.
50. Zhang, Y.; McCluskey, K.; Fujii, K.; Wahl, L. M., Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte-macrophage CSF, and IL-1 beta through prostaglandin-dependent and-independent mechanisms. J. Immunol., 1998, 161(6), 3071-3076.
51. Mauviel, A.; Chung, K. Y.; Agarwal, A.; Tamai, K.; Uitto, J., Cellspecific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J. Biol. Chem., 1996, 271(18), 10917-10923.
52. Ye, S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol., 2000, 19(7), 623-629.
53. Corcoran, M. L.; Stetler-Stevenson, W. G.; DeWitt, D. L.; Wahl, L. M. Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes. Arch. Biochem. Biophys., 1994, 310(2), 481-488.
54. Galis, Z. S.; Sukhova, G. K.; Lark, M. W.; Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94(6), 2493-2503.
55. Libby, P.; Galis, Z. S. Cytokines regulate genes involved in atherogenesis. Ann. NY. Acad. Sci., 1995, 748, 158-168; discussion 168-70.
56. Herman, M. P.; Sukhova, G. K.; Kisiel, W.; Foster, D.; Kehry, M. R.; Libby, P.; Schonbeck, U. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J. Clin. Invest., 2001, 107(9), 1117-1126.
57. S, S. J.; Danielson, S. K. Tomacufous neuropathies. J. Clin. Neuromuscul. Dis., 2000, 2(1), 59-60.
58. Xu, X. P.; Meisel, S. R.; Ong, J. M.; Kaul, S.; Cercek, B.; Rajavashisth, T. B.; Sharifi, B.; Shah, P. K. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation, 1999, 99(8), 993-998.
59. Chen, K. C.; Wang, Y. S.; Hu, C. Y.; Chang, W. C.; Liao, Y. C.; Dai, C. Y.; Juo, S. H. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. FASEB J., 2011, 25(5), 1718-1728.
60. Damas, J. K.; Waehre, T.; Yndestad, A.; Ueland, T.; Muller, F.; Eiken, H. G.; Holm, A. M.; Halvorsen, B.; Froland, S. S.; Gullestad, L.; Aukrust, P., Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation, 2002, 106(1), 36-42.
61. Siwik, D. A.; Chang, D. L.; Colucci, W. S. Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res., 2000, 86(12), 1259-1265.
62. Li, Y. Y.; McTiernan, C. F.; Feldman, A. M. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc. Res., 2000, 46(2), 214-224.
63. Bassiouny, H. S.; Song, R. H.; Hong, X. F.; Singh, A.; Kocharyan, H.; Glagov, S., Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation, 1998, 98(2), 157-163.
64. Godin, D.; Ivan, E.; Johnson, C.; Magid, R.; Galis, Z. S. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation, 2000, 102(23), 2861-2866.
65. Chesler, N. C.; Ku, D. N.; Galis, Z. S. Transmural pressure induces matrix-degrading activity in porcine arteries ex vivo. Am. J. Physiol., 1999, 277(5 Pt 2), H2002-2009.
66. Okamoto, T.; Akaike, T.; Nagano, T.; Miyajima, S.; Suga, M.; Ando, M.; Ichimori, K.; Maeda, H. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch. Biochem. Biophys., 1997, 342(2), 261-274.
67. Tronc, F.; Mallat, Z.; Lehoux, S.; Wassef, M.; Esposito, B.; Tedgui, A., Role of matrix metalloproteinases in blood flowinduced arterial enlargement: interaction with NO. Arterioscler Thromb. Vasc. Biol., 2000, 20(12), E120-126.
68. Cai, H.; Harrison, D. G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res., 2000, 87(10), 840-844.
69. Frears, E. R.; Zhang, Z.; Blake, D. R.; O'Connell, J. P.; Winyard, P. G. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett., 1996, 381(1-2), 21-24.
70. Rajagopalan, S.; Meng, X. P.; Ramasamy, S.; Harrison, D. G.; Galis, Z. S., Reactive oxygen species produced by macrophagederived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest., 1996, 98(11), 2572-2579.
71. Zempo, N.; Kenagy, R. D.; Au, Y. P.; Bendeck, M.; Clowes, M. M.; Reidy, M. A.; Clowes, A. W. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J. Vasc. Surg., 1994, 20(2), 209-217.
72. Bendeck, M. P.; Zempo, N.; Clowes, A. W.; Galardy, R. E.; Reidy, M. A. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res., 1994, 75 (3), 539-45.
73. Forough, R.; Koyama, N.; Hasenstab, D.; Lea, H.; Clowes, M.; Nikkari, S. T.; Clowes, A. W. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res., 1996, 79(4), 812-820.
74. Southgate, K. M.; Fisher, M.; Banning, A. P.; Thurston, V. J.; Baker, A. H.; Fabunmi, R. P.; Groves, P. H.; Davies, M.; Newby, A. C. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ. Res., 1996, 79(6), 1177-1187.
75. Tavakoli, S.; Razavian, M.; Zhang, J.; Nie, L.; Marfatia, R.; Dobrucki, L. W.; Sinusas, A. J.; Robinson, S.; Edwards, D. S.; Sadeghi, M. M. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb. Vasc. Biol., 2011, 31(1), 102-109.
76. Sundstrom, J.; Evans, J. C.; Benjamin, E. J.; Levy, D.; Larson, M. G.; Sawyer, D. B.; Siwik, D. A.; Colucci, W. S.; Sutherland, P.; Wilson, P. W.; Vasan, R. S. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 2004, 109(23), 2850-2856.
77. Abboud, R. T.; Fera, T.; Johal, S.; Richter, A.; Gibson, N. Effect of smoking on plasma neutrophil elastase levels. J. Lab. Clin. Med., 1986, 108(4), 294-300.
78. Sundstrom, J.; Evans, J. C.; Benjamin, E. J.; Levy, D.; Larson, M. G.; Sawyer, D. B.; Siwik, D. A.; Colucci, W. S.; Wilson, P. W.; Vasan, R. S. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur. Heart J., 2004, 25(17), 1509-1516.
79. Nakamura, T.; Ebihara, I.; Shimada, N.; Koide, H., Effect of cigarette smoking on plasma metalloproteinase-9 concentration. Clin. Chim. Acta., 1998, 276(2), 173-177.
80. Koh, K. K.; Ahn, J. Y.; Kang, M. H.; Kim, D. S.; Jin, D. K.; Sohn, M. S.; Park, G. S.; Choi, I. S.; Shin, E. K., Effects of hormone replacement therapy on plaque stability, inflammation, andfibrinolysis in hypertensive or overweight postmenopausal women. Am. J. Cardiol., 2001, 88(12), 1423-1426, A8.
81. Kalela, A.; Ponnio, M.; Koivu, T. A.; Hoyhtya, M.; Huhtala, H.; Sillanaukee, P.; Nikkari, S. T. Association of serum sialic acid and MMP-9 with lipids and inflammatory markers. Eur. J. Clin. Invest., 2000, 30(2), 99-104.
82. Marx, N.; Froehlich, J.; Siam, L.; Ittner, J.; Wierse, G.; Schmidt, A.; Scharnagl, H.; Hombach, V.; Koenig, W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb. Vasc. Biol., 2003, 23(2), 283-288.
83. Papazafiropoulou, A.; Perrea, D.; Moyssakis, I.; Kokkinos, A.; Katsilambros, N.; Tentolouris, N. Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J. Diabetes Complications 24(1), 20-27.
84. Katsuda, S.; Kaji, T. Atherosclerosis and extracellular matrix. J. Atheroscler Thromb., 2003, 10(5), 267-274.
85. Lander, E. S.; Linton, L. M.; Birren, B.; Nusbaum, C.; Zody, M. C.; Baldwin, J.; Devon, K.; Dewar, K.; Doyle, M.; FitzHugh, W.; Funke, R.; Gage, D.; Harris, K.; Heaford, A.; Howland, J.; Kann, L.; Lehoczky, J.; LeVine, R.; McEwan, P.; McKernan, K.; Meldrim, J.; Mesirov, J. P.; Miranda, C.; Morris, W.; Naylor, J.; Raymond, C.; Rosetti, M.; Santos, R.; Sheridan, A.; Sougnez, C.; Stange-Thomann, N.; Stojanovic, N.; Subramanian, A.; Wyman, D.; Rogers, J.; Sulston, J.; Ainscough, R.; Beck, S.; Bentley, D.; Burton, J.; Clee, C.; Carter, N.; Coulson, A.; Deadman, R.; Deloukas, P.; Dunham, A.; Dunham, I.; Durbin, R.; French, L.; Grafham, D.; Gregory, S.; Hubbard, T.; Humphray, S.; Hunt, A.; Jones, M.; Lloyd, C.; McMurray, A.; Matthews, L.; Mercer, S.; Milne, S.; Mullikin, J. C.; Mungall, A.; Plumb, R.; Ross, M.; Shownkeen, R.; Sims, S.; Waterston, R. H.; Wilson, R. K.; Hillier, L. W.; McPherson, J. D.; Marra, M. A.; Mardis, E. R.; Fulton, L. A.; Chinwalla, A. T.; Pepin, K. H.; Gish, W. R.; Chissoe, S. L.; Wendl, M. C.; Delehaunty, K. D.; Miner, T. L.; Delehaunty, A.; Kramer, J. B.; Cook, L. L.; Fulton, R. S.; Johnson, D. L.; Minx, P. J.; Clifton, S. W.; Hawkins, T.; Branscomb, E.; Predki, P.; Richardson, P.; Wenning, S.; Slezak, T.; Doggett, N.; Cheng, J. F.; Olsen, A.; Lucas, S.; Elkin, C.; Uberbacher, E.; Frazier, M.; Gibbs, R. A.; Muzny, D. M.; Scherer, S. E.; Bouck, J. B.; Sodergren, E. J.; Worley, K. C.; Rives, C. M.; Gorrell, J. H.; Metzker, M. L.; Naylor, S. L.; Kucherlapati, R. S.; Nelson, D. L.; Weinstock, G. M.; Sakaki, Y.; Fujiyama, A.; Hattori, M.; Yada, T.; Toyoda, A.; Itoh, T.; Kawagoe, C.; Watanabe, H.; Totoki, Y.; Taylor, T.; Weissenbach, J.; Heilig, R.; Saurin, W.; Artiguenave, F.; Brottier, P.; Bruls, T.; Pelletier, E.; Robert, C.; Wincker, P.; Smith, D. R.; Doucette-Stamm, L.; Rubenfield, M.; Weinstock, K.; Lee, H. M.; Dubois, J.; Rosenthal, A.; Platzer, M.; Nyakatura, G.; Taudien, S.; Rump, A.; Yang, H.; Yu, J.; Wang, J.; Huang, G.; Gu, J.; Hood, L.; Rowen, L.; Madan, A.; Qin, S.; Davis, R. W.; Federspiel, N. A.; Abola, A. P.; Proctor, M. J.; Myers, R. M.; Schmutz, J.; Dickson, M.; Grimwood, J.; Cox, D. R.; Olson, M. V.; Kaul, R.; Shimizu, N.; Kawasaki, K.; Minoshima, S.; Evans, G. A.; Athanasiou, M.; Schultz, R.; Roe, B. A.; Chen, F.; Pan, H.; Ramser, J.; Lehrach, H.; Reinhardt, R.; McCombie, W. R.; de la Bastide, M.; Dedhia, N.; Blocker, H.; Hornischer, K.; Nordsiek, G.; Agarwala, R.; Aravind, L.; Bailey, J. A.; Bateman, A.; Batzoglou, S.; Birney, E.; Bork, P.; Brown, D. G.; Burge, C. B.; Cerutti, L.; Chen, H. C.; Church, D.; Clamp, M.; Copley, R. R.; Doerks, T.; Eddy, S. R.; Eichler, E. E.; Furey, T. S.; Galagan, J.; Gilbert, J. G.; Harmon, C.; Hayashizaki, Y.; Haussler, D.; Hermjakob, H.; Hokamp, K.; Jang, W.; Johnson, L. S.; Jones, T. A.; Kasif, S.; Kaspryzk, A.; Kennedy, S.; Kent, W. J.; Kitts, P.; Koonin, E. V.; Korf, I.; Kulp, D.; Lancet, D.; Lowe, T. M.; McLysaght, A.; Mikkelsen, T.; Moran, J. V.; Mulder, N.; Pollara, V. J.; Ponting, C. P.; Schuler, G.; Schultz, J.; Slater, G.; Smit, A. F.; Stupka, E.; Szustakowski, J.; Thierry-Mieg, D.; Thierry-Mieg, J.; Wagner, L.; Wallis, J.; Wheeler, R.; Williams, A.; Wolf, Y. I.; Wolfe, K. H.; Yang, S. P.; Yeh, R. F.; Collins, F.; Guyer, M. S.; Peterson, J.; Felsenfeld, A.; Wetterstrand, K. A.; Patrinos, A.; Morgan, M. J.; de Jong, P.; Catanese, J. J.; Osoegawa, K.; Shizuya, H.; Choi, S.; Chen, Y. J. Initial sequencing and analysis of the human genome. Nature, 2001, 409(6822), 860-921.
86. Plenz, G. A.; Deng, M. C.; Robenek, H.; Volker, W. Vascular collagens: spotlight on the role of type VIII collagen in atherogenesis. Atherosclerosis, 2003, 166(1), 1-11.
87. Lyons, A. J.; Jones, J. Cell adhesion molecules, the extracellular matrix and oral squamous carcinoma. Int. J. Oral. Maxillofac. Surg., 2007, 36(8), 671-679.
88. Siasos, G.; Tousoulis, D.; Vlachopoulos, C.; Antoniades, C.; Stefanadi, E.; Ioakeimidis, N.; Zisimos, K.; Siasou, Z.; Papavassiliou, A. G.; Stefanadis, C. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. Am. J. Hypertens., 2009, 22(6), 586-592.
89. Siasos, G.; Tousoulis, D.; Siasou, Z.; Stefanadis, C.; Papavassiliou, A. G. Shear stress, protein kinases and atherosclerosis. Curr. Med. Chem., 2007, 14(14), 1567-1572.
90. Siasos, G.; Tousoulis, D.; Vlachopoulos, C.; Antoniades, C.; Stefanadi, E.; Ioakeimidis, N.; Andreou, I.; Zisimos, K.; Papavassiliou, A. G.; Stefanadis, C. Short-term treatment with Larginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. Int. J. Cardiol., 2008, 126(3), 394-399.
91. Vlachopoulos, C.; Kosmopoulou, F.; Alexopoulos, N.; Ioakeimidis, N.; Siasos, G.; Stefanadis, C. Acute mental stress has a prolonged unfavorable effect on arterial stiffness and wave reflections. Psychosom. Med., 2006, 68(2), 231-237.
92. Woods, A. A.; Linton, S. M.; Davies, M. J. Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem. J., 2003, 370(Pt 2), 729-735.
93. Nakashima, Y.; Fujii, H.; Sumiyoshi, S.; Wight, T. N.; Sueishi, K., Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb. Vasc. Biol., 2007, 27(5), 1159-1165.
94. Davies, M. J.; Thomas, A. C. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J., 1985, 53(4), 363-373.
95. Raines, E. W. The extracellular matrix can regulate vascular cell migration, proliferation, and survival: relationships to vascular disease. Int. J. Exp. Pathol., 2000, 81(3), 173-182.
96. Kolodgie, F. D.; Burke, A. P.; Wight, T. N.; Virmani, R. The accumulation of specific types of proteoglycans in eroded plaques: a role in coronary thrombosis in the absence of rupture. Curr. Opin. Lipidol., 2004, 15(5), 575-582.
97. Kolodgie, F. D.; Burke, A. P.; Farb, A.; Weber, D. K.; Kutys, R.; Wight, T. N.; Virmani, R. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler. Thromb. Vasc. Biol., 2002, 22(10), 1642-1648.
98. Glass, C. K.; Witztum, J. L. Atherosclerosis. the road ahead. Cell, 2001, 104(4), 503-516.
99. Libby, P. Changing concepts of atherogenesis. J. Intern. Med., 2000, 247(3), 349-358.
100. Orford, J. L.; Selwyn, A. P.; Ganz, P.; Popma, J. J.; Rogers, C. The comparative pathobiology of atherosclerosis and restenosis. Am. J. Cardiol., 2000, 86(4B), 6H-11H.
101. Tousoulis, D.; Antoniades, C.; Stefanadis, C. Assessing inflammatory status in cardiovascular disease. Heart 2007, 93(8), 1001-1007.
102. Krauss, R. M. Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol., 1998, 81(4A), 13B-17B.
103. Tousoulis, D.; Kampoli, A. M.; Stefanadi, E.; Antoniades, C.; Siasos, G.; Papavassiliou, A. G.; Stefanadis, C. New biochemical markers in acute coronary syndromes. Curr Med Chem 2008, 15(13), 1288-1296.
104. Tousoulis, D.; Antoniades, C.; Nikolopoulou, A.; Koniari, K.; Vasiliadou, C.; Marinou, K.; Koumallos, N.; Papageorgiou, N.; Stefanadi, E.; Siasos, G.; Stefanadis, C. Interaction between cytokines and sCD40L in patients with stable and unstable coronary syndromes. Eur. J. Clin. Invest., 2007, 37(8), 623-628.
105. Stary, H. C.; Chandler, A. B.; Dinsmore, R. E.; Fuster, V.; Glagov, S.; Insull, W., Jr.; Rosenfeld, M. E.; Schwartz, C. J.; Wagner, W. D.; Wissler, R. W. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation, 1995, 92(5), 1355-1374.
106. Stary, H. C.; Chandler, A. B.; Dinsmore, R. E.; Fuster, V.; Glagov, S.; Insull, W., Jr.; Rosenfeld, M. E.; Schwartz, C. J.; Wagner, W. D.; Wissler, R. W. A definition of advanced types ofatherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol., 1995, 15(9), 1512-1531.
107. Ross, R. Atherosclerosis--an inflammatory disease. N. Engl. J. Med., 1999, 340(2), 115-126.
108. Finn, A. V.; Nakano, M.; Narula, J.; Kolodgie, F. D.; Virmani, R., Concept of vulnerable/unstable plaque. Arterioscler Thromb. Vasc. Biol., 30(7), 1282-1292.
109. Antoniades, C.; Tousoulis, D.; Marinou, K.; Papageorgiou, N.; Bosinakou, E.; Tsioufis, C.; Stefanadi, E.; Latsios, G.; Tentolouris, C.; Siasos, G.; Stefanadis, C. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin. Cardiol., 2007, 30(6), 295-300.
110. Tousoulis, D.; Boger, R. H.; Antoniades, C.; Siasos, G.; Stefanadi, E.; Stefanadis, C. Mechanisms of disease: L-arginine in coronary atherosclerosis--a clinical perspective. Nat. Clin. Pract. Cardiovasc. Med., 2007, 4(5), 274-283.
111. Ravn, H. B.; Falk, E. Histopathology of plaque rupture. Cardiol. Clin., 1999, 17(2), 263-270, vii.
112. Halpert, I.; Sires, U. I.; Roby, J. D.; Potter-Perigo, S.; Wight, T. N.; Shapiro, S. D.; Welgus, H. G.; Wickline, S. A.; Parks, W. C. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. USA, 1996, 93(18), 9748-9753.
113. Lemaitre, V.; O'Byrne, T. K.; Borczuk, A. C.; Okada, Y.; Tall, A. R.; D'Armiento, J. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J. Clin. Invest., 2001, 107(10), 1227-1234.
114. Herman, M. P.; Sukhova, G. K.; Libby, P.; Gerdes, N.; Tang, N.; Horton, D. B.; Kilbride, M.; Breitbart, R. E.; Chun, M.; Schonbeck, U. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation, 2001, 104(16), 1899-1904.
115. Turu, M. M.; Krupinski, J.; Catena, E.; Rosell, A.; Montaner, J.; Rubio, F.; Alvarez-Sabin, J.; Cairols, M.; Badimon, L. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis, 2006, 187(1), 161-169.
116. Tuomainen, A. M.; Nyyssonen, K.; Laukkanen, J. A.; Tervahartiala, T.; Tuomainen, T. P.; Salonen, J. T.; Sorsa, T.; Pussinen, P. J. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler. Thromb. Vasc. Biol., 2007, 27(12), 2722-2728.
117. Laxton, R. C.; Hu, Y.; Duchene, J.; Zhang, F.; Zhang, Z.; Leung, K. Y.; Xiao, Q.; Scotland, R. S.; Hodgkinson, C. P.; Smith, K.; Willeit, J.; Lopez-Otin, C.; Simpson, I. A.; Kiechl, S.; Ahluwalia, A.; Xu, Q.; Ye, S. A role of matrix metalloproteinase-8 in atherosclerosis. Circ. Res., 2009, 105(9), 921-929.
118. Galis, Z. S.; Sukhova, G. K.; Kranzhofer, R.; Clark, S.; Libby, P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA, 1995, 92(2), 402-406.
119. Galis, Z. S.; Muszynski, M.; Sukhova, G. K.; Simon-Morrissey, E.; Libby, P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann. NY. Acad. Sci., 1995, 748, 501-507.
120. Silence, J.; Lupu, F.; Collen, D.; Lijnen, H. R., Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb. Vasc. Biol., 2001, 21(9), 1440-1445.
121. Lijnen, H. R.; Soloway, P.; Collen, D. Tissue inhibitor of matrix metalloproteinases-1 impairs arterial neointima formation after vascular injury in mice. Circ. Res., 1999, 85(12), 1186-1191.
122. Lijnen, H. R.; Van Hoef, B.; Vanlinthout, I.; Verstreken, M.; Rio, M. C.; Collen, D. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler. Thromb. Vasc. Biol., 1999, 19(12), 2863-2870.
123. Morgan, A. R.; Zhang, B.; Tapper, W.; Collins, A.; Ye, S. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J. Mol. Med., 2003, 81(5), 321-326.
124. Cho, H. J.; Chae, I. H.; Park, K. W.; Ju, J. R.; Oh, S.; Lee, M. M.; Park, Y. B. Functional polymorphism in the promoter region of the gelatinase B gene in relation to coronary artery disease and restenosis after percutaneous coronary intervention. J. Hum. Genet., 2002, 47(2), 88-91.
125. Beyzade, S.; Zhang, S.; Wong, Y. K.; Day, I. N.; Eriksson, P.; Ye, S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol., 2003, 41(12), 2130-2137.
126. Zhou, X.; Huang, J.; Chen, J.; Su, S.; Chen, R.; Gu, D. Haplotype analysis of the matrix metalloproteinase 3 gene and myocardial infarction in a Chinese Han population. The Beijing atherosclerosis study. Thromb. Haemost., 2004, 92(4), 867-873.
127. Brown, D. L.; Hibbs, M. S.; Kearney, M.; Loushin, C.; Isner, J. M. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation, 1995, 91(8), 2125-2131.
128. Zhang, B.; Ye, S.; Herrmann, S. M.; Eriksson, P.; de Maat, M.; Evans, A.; Arveiler, D.; Luc, G.; Cambien, F.; Hamsten, A.; Watkins, H.; Henney, A. M. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation, 1999, 99(14), 1788-1794.
129. Noji, Y.; Kajinami, K.; Kawashiri, M. A.; Todo, Y.; Horita, T.; Nohara, A.; Higashikata, T.; Inazu, A.; Koizumi, J.; Takegoshi, T.; Mabuchi, H. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin. Chem. Lab. Med., 2001, 39(5), 380-384.
130. Blankenberg, S.; Rupprecht, H. J.; Poirier, O.; Bickel, C.; Smieja, M.; Hafner, G.; Meyer, J.; Cambien, F.; Tiret, L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 2003, 107(12), 1579-1585.
131. Imai, K.; Yokohama, Y.; Nakanishi, I.; Ohuchi, E.; Fujii, Y.; Nakai, N.; Okada, Y., Matrix met-aletal/et-alloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J. Biol. Chem., 1995, 270(12), 6691-6697.
132. He, C. S.; Wilhelm, S. M.; Pentland, A. P.; Marmer, B. L.; Grant, G. A.; Eisen, A. Z.; Goldberg, G. I. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc. Natl. Acad. Sci. USA, 1989, 86(8), 2632-2636.
133. Suzuki, K.; Enghild, J. J.; Morodomi, T.; Salvesen, G.; Nagase, H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry, 1990, 29(44), 10261-10270.
134. Pei, D.; Weiss, S. J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature, 1995, 375(6528), 244-247.
135. Sato, H.; Kinoshita, T.; Takino, T.; Nakayama, K.; Seiki, M. Activation of a recombinant membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)-2. FEBS. Lett., 1996, 393(1), 101-104.
136. Williamson, R. A.; Marston, F. A.; Angal, S.; Koklitis, P.; Panico, M.; Morris, H. R.; Carne, A. F.; Smith, B. J.; Harris, T. J.; Freedman, R. B. Disulphide bond assignment in human tissue inhibitor of metalloproteinases (TIMP). Biochem. J., 1990, 268(2), 267-274.
137. Wu, K.; Setty, S.; Mauer, S. M.; Killen, P.; Nagase, H.; Michael, A. F.; Tsilibary, E. C. Altered kidney matrix gene expression in early stages of experimental diabetes. Acta. Anat. (Basel), 1997, 158(3), 155-165.
138. Schaefer, L.; Han, X.; Gretz, N.; Hafner, C.; Meier, K.; Matzkies, F.; Schaefer, R. M. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. Kidney Int., 1996, 49(1), 75-81.
139. Li, Y. Y.; McTiernan, C. F.; Feldman, A. M. Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc. Res., 1999, 42(1), 162-172.
140. Chua, P. K.; Melish, M. E.; Yu, Q.; Yanagihara, R.; Yamamoto, K. S.; Nerurkar, V. R. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin. Diagn. Lab. Immunol., 2003, 10(2), 308-314.
141. Carome, M. A.; Striker, L. J.; Peten, E. P.; Moore, J.; Yang, C. W.; Stetler-Stevenson, W. G.; Striker, G. E. Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am. J. Physiol., 1993, 264(6 Pt 2), F923-929.
142. Chakraborti, S.; Mandal, A.; Das, S.; Chakraborti, T. Inhibition of Na+/Ca2+ exchanger by peroxynitrite in microsomes of pulmonary smooth muscle: role of matrix metalloproteinase-2. Biochim. Biophys. Acta. 2004, 1671(1-3), 70-78.
143. Leco, K. J.; Khokha, R.; Pavloff, N.; Hawkes, S. P.; Edwards, D. R. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem., 1994, 269(12), 9352-9360.
144. Dollery, C. M.; McEwan, J. R.; Henney, A. M. Matrix metalloproteinases and cardiovascular disease. Circ. Res., 1995, 77(5), 863-868.
145. Carlyle, W. C.; Jacobson, A. W.; Judd, D. L.; Tian, B.; Chu, C.; Hauer, K. M.; Hartman, M. M.; McDonald, K. M. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J. Mol. Cell Cardiol., 1997, 29(9), 2451-2463.
146. Cleutjens, J. P.; Kandala, J. C.; Guarda, E.; Guntaka, R. V.; Weber, K. T. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell Cardiol., 1995, 27(6), 1281-1292.
147. Tyagi, S. C.; Kumar, S. G.; Haas, S. J.; Reddy, H. K.; Voelker, D. J.; Hayden, M. R.; Demmy, T. L.; Schmaltz, R. A.; Curtis, J. J. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell Cardiol., 1996, 28(7), 1415-1428.
148. Sato, S.; Ashraf, M.; Millard, R. W.; Fujiwara, H.; Schwartz, A. Connective tissue changes in early ischemia of porcine myocardium: an ultrastructural study. J. Mol. Cell Cardiol., 1983, 15(4), 261-275.
149. Danielsen, C. C.; Wiggers, H.; Andersen, H. R. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J. Mol. Cell Cardiol., 1998, 30(7), 1431-1442.
150. Tyagi, S. C.; Matsubara, L.; Weber, K. T. Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin. Biochem., 1993, 26(3), 191-198.
151. Heymans, S.; Luttun, A.; Nuyens, D.; Theilmeier, G.; Creemers, E.; Moons, L.; Dyspersin, G. D.; Cleutjens, J. P.; Shipley, M.; Angellilo, A.; Levi, M.; Nube, O.; Baker, A.; Keshet, E.; Lupu, F.; Herbert, J. M.; Smits, J. F.; Shapiro, S. D.; Baes, M.; Borgers, M.; Collen, D.; Daemen, M. J.; Carmeliet, P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med., 1999, 5(10), 1135-1142.
152. Ducharme, A.; Frantz, S.; Aikawa, M.; Rabkin, E.; Lindsey, M.; Rohde, L. E.; Schoen, F. J.; Kelly, R. A.; Werb, Z.; Libby, P.; Lee, R. T. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest., 2000, 106(1), 55-62.
153. Thomas, C. V.; Coker, M. L.; Zellner, J. L.; Handy, J. R.; Crumbley, A. J., III.; Spinale, F. G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation, 1998, 97(17), 1708-1715.
154. Tyagi, S. C.; Kumar, S.; Voelker, D. J.; Reddy, H. K.; Janicki, J. S.; Curtis, J. J. Differential gene expression of extracellular matrix components in dilated cardiomyopathy. J. Cell Biochem., 1996, 63(2), 185-198.
155. Spinale, F. G.; Coker, M. L.; Thomas, C. V.; Walker, J. D.; Mukherjee, R.; Hebbar, L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ. Res., 1998, 82(4), 482-495.
156. Li, Y. Y.; Feldman, A. M.; Sun, Y.; McTiernan, C. F. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation, 1998, 98(17), 1728-1734.
157. Coker, M. L.; Thomas, C. V.; Clair, M. J.; Hendrick, J. W.; Krombach, R. S.; Galis, Z. S.; Spinale, F. G. Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am. J. Physiol., 1998, 274(5 Pt 2), H1516-1523.
158. Spinale, F. G.; Coker, M. L.; Krombach, S. R.; Mukherjee, R.; Hallak, H.; Houck, W. V.; Clair, M. J.; Kribbs, S. B.; Johnson, L. L.; Peterson, J. T.; Zile, M. R. Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ. Res., 1999, 85(4), 364-376.
159. Kim, H. E.; Dalal, S. S.; Young, E.; Legato, M. J.; Weisfeldt, M. L.; D'Armiento, J., Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J. Clin. Invest., 2000, 106(7), 857-866.
160. Lehoux, S.; Lemarie, C. A.; Esposito, B.; Lijnen, H. R.; Tedgui, A. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation, 2004, 109(8), 1041-1047.
161. Thompson, R. W.; Parks, W. C. Role of matrix metalloproteinases in abdominal aortic aneurysms. Ann. NY. Acad. Sci., 1996, 800, 157-174.
162. Boden, N.; Cheng, Y.; Knowles, P. F. Equilibrium and nonequilibrium conformations of peptides in lipid bilayers. Biophys. Chem., 1997, 65(2-3), 205-210.
163. Patel, M. I.; Melrose, J.; Ghosh, P.; Appleberg, M. Increased synthesis of matrix metalloproteinases by aortic smooth muscle cells is implicated in the etiopathogenesis of abdominal aortic aneurysms. J. Vasc. Surg., 1996, 24(1), 82-92.
164. McMillan, W. D.; Tamarina, N. A.; Cipollone, M.; Johnson, D. A.; Parker, M. A.; Pearce, W. H. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation, 1997, 96(7), 2228-2232.
165. Pyo, R.; Lee, J. K.; Shipley, J. M.; Curci, J. A.; Mao, D.; Ziporin, S. J.; Ennis, T. L.; Shapiro, S. D.; Senior, R. M.; Thompson, R. W. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J. Clin. Invest., 2000, 105(11), 1641-1649.
166. Eickelberg, O.; Roth, M.; Mussmann, R.; Rudiger, J. J.; Tamm, M.; Perruchoud, A. P.; Block, L. H. Calcium channel blockers activate the interleukin-6 gene via the transcription factors NF-IL6 and NFkappaB in primary human vascular smooth muscle cells. Circulation, 1999, 99(17), 2276-2282.
167. Papakonstantinou, E.; Roth, M.; Kokkas, B.; Papadopoulos, C.; Karakiulakis, G. Losartan inhibits the angiotensin II-induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 2001, 38(5), 715-728.
168. Funck, R. C.; Wilke, A.; Rupp, H.; Brilla, C. G. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv. Exp. Med. Biol., 1997, 432, 35-44.
169. Tyagi, S. C.; Kumar, S.; Katwa, L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J. Mol. Cell Cardiol., 1997, 29(1), 391-404.
170. Death, A. K.; Nakhla, S.; McGrath, K. C.; Martell, S.; Yue, D. K.; Jessup, W.; Celermajer, D. S. Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J. Am. Coll. Cardiol., 2002, 39(12), 1943-1950.
171. Tousoulis, D.; Antoniades, C.; Vasiliadou, C.; Kourtellaris, P.; Koniari, K.; Marinou, K.; Charakida, M.; Ntarladimas, I.; Siasos, G.; Stefanadis, C. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart, 2007, 93(2), 244-246.
172. Tousoulis, D.; Charakida, M.; Stefanadi, E.; Siasos, G.; Latsios, G.; Stefanadis, C., Statins in heart failure. Beyond the lipid lowering effect. Int. J. Cardiol., 2007, 115(2), 144-150.
173. Ikeda, U.; Shimpo, M.; Ohki, R.; Inaba, H.; Takahashi, M.; Yamamoto, K.; Shimada, K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension, 2000, 36(3), 325-329.
174. Bellosta, S.; Via, D.; Canavesi, M.; Pfister, P.; Fumagalli, R.; Paoletti, R.; Bernini, F. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol., 1998, 18(11), 1671-1678.
175. Crisby, M.; Nordin-Fredriksson, G.; Shah, P. K.; Yano, J.; Zhu, J.; Nilsson, J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation, 2001, 103(7), 926-933.
176. Cipollone, F.; Fazia, M.; Iezzi, A.; Zucchelli, M.; Pini, B.; De Cesare, D.; Ucchino, S.; Spigonardo, F.; Bajocchi, G.; Bei, R.; Muraro, R.; Artese, L.; Piattelli, A.; Chiarelli, F.; Cuccurullo, F.; Mezzetti, A. Suppression of the functionally coupledcyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation, 2003, 107(11), 1479-1485.
177. Ceron, C. S.; Castro, M. M.; Rizzi, E.; Montenegro, M. F.; Fontana, V.; Salgado, M. C.; Gerlach, R. F.; Tanus-Santos, J. E. Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension. Br. J. Pharmacol., 2010, 160(1), 77-87.
178. Li, M. J.; Huang, C. X.; Okello, E.; Yanhong, T.; Mohamed, S. Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Can. J. Cardiol., 2009, 25(9), 523-526.
179. Weir, R. A.; Mark, P. B.; Petrie, C. J.; Clements, S.; Steedman, T.; Ford, I.; Ng, L. L.; Squire, I. B.; Wagner, G. S.; McMurray, J. J.; Dargie, H. J. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am. Heart J., 2009, 157(6), 1088-1096.
180. Derosa, G.; Maffioli, P.; D'Angelo, A.; Salvadeo, S. A.; Ferrari, I.; Fogari, E.; Gravina, A.; Mereu, R.; Randazzo, S.; Cicero, A. F., Effects of long chain omega-3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. Expert Opin. Pharmacother., 2009, 10(8), 1239-1247.
181. Shinto, L.; Marracci, G.; Baldauf-Wagner, S.; Strehlow, A.; Yadav, V.; Stuber, L.; Bourdette, D. Omega-3 fatty acid supplementation decreases matrix metalloproteinase-9 production in relapsingremitting multiple sclerosis. Prostaglandins Leukot. Essent. Fatty Acids, 2009, 80(2-3), 131-136.
182. Zainal, Z.; Longman, A. J.; Hurst, S.; Duggan, K.; Caterson, B.; Hughes, C. E.; Harwood, J. L. Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis. Osteoarthritis Cartilage, 2009, 17(7), 896-905.
183. Wu, T. C.; Chen, Y. H.; Leu, H. B.; Chen, Y. L.; Lin, F. Y.; Lin, S. J.; Chen, J. W. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and-9 in experimental atherosclerosis. Free Radic. Biol. Med., 2007, 43(11), 1508-1522.
184. Ammarguellat, F. Z.; Gannon, P. O.; Amiri, F.; Schiffrin, E. L. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension, 2002, 39(2 Pt 2), 679-684.
185. Tang, X. Y.; Liu, Q.; Dai, D. Z.; Dai, Y. CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium. Pharmacol. Rep., 2008, 60(4), 524-531.
186. Sachidanandam, K.; Portik-Dobos, V.; Harris, A. K.; Hutchinson, J. R.; Muller, E.; Johnson, M. H.; Ergul, A. Evidence for vasculoprotective effects of ETB receptors in resistance artery remodeling in diabetes. Diabetes, 2007, 56(11), 2753-2758.
187. Spiers, J. P.; Kelso, E. J.; Siah, W. F.; Edge, G.; Song, G.; McDermott, B. J.; Hennessy, M. Alterations in vascular matrix metalloproteinase due to ageing and chronic hypertension: effects of endothelin receptor blockade. J. Hypertens, 2005, 23(9), 1717-1724.
188. Potier, M.; Elliot, S. J.; Tack, I.; Lenz, O.; Striker, G. E.; Striker, L. J.; Karl, M. Expression and regulation of estrogen receptors in mesangial cells: influence on matrix metalloproteinase-9. J. Am. Soc. Nephrol., 2001, 12(2), 241-251.
189. Ardans, J. A.; Blum, A.; Mangan, P. R.; Wientroub, S.; Cannon, R. O., III.; Wahl, L. M. Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes. Arterioscler. Thromb. Vasc. Biol., 2001, 21(8), 1265-1268.
190. Mueck, A. O.; Seeger, H.; Wallwiener, D. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause, 2002, 9(4), 273-281.
191. Zanger, D.; Yang, B. K.; Ardans, J.; Waclawiw, M. A.; Csako, G.; Wahl, L. M.; Cannon, R. O. III., Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J. Am. Coll. Cardiol., 2000, 36(6), 1797-1802.
192. Keller, N. R.; Sierra-Rivera, E.; Eisenberg, E.; Osteen, K. G. Progesterone exposure prevents matrix metalloproteinase-3 (MMP-3) stimulation by interleukin-1alpha in human endometrial stromal cells. J. Clin. Endocrinol. Metab., 2000, 85(4), 1611-1619.
193. Rossouw, J. E.; Anderson, G. L.; Prentice, R. L.; LaCroix, A. Z.; Kooperberg, C.; Stefanick, M. L.; Jackson, R. D.; Beresford, S. A.; Howard, B. V.; Johnson, K. C.; Kotchen, J. M.; Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288(3), 321-333.
194. Mukherjee, D.; Nissen, S. E.; Topol, E. J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA, 2001, 286(8), 954-959.
195. Tousoulis, D.; Drolias, A.; Antoniades, C.; Vasiliadou, C.; Marinou, K.; Latsios, G.; Stefanadi, E.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Trikas, A.; Stefanadis, C. Antidepressive treatment as a modulator of inflammatory process in patients with heart failure: effects on proinflammatory cytokines and acute phase protein levels. Int. J. Cardiol., 2009, 134(2), 238-243.
196. Oikonomou, E.; Tousoulis, D.; Siasos, G.; Zaromitidou, M.; Papavassiliou, A. G.; Stefanadis, C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic. J. Cardiol., 2011, 52(1), 30-40.
197. Rohde, L. E.; Ducharme, A.; Arroyo, L. H.; Aikawa, M.; Sukhova, G. H.; Lopez-Anaya, A.; McClure, K. F.; Mitchell, P. G.; Libby, P.; Lee, R. T. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation, 1999, 99(23), 3063-3070.
198. Feldman, M. D.; Erikson, J. M.; Mao, Y.; Korcarz, C. E.; Lang, R. M.; Freeman, G. L. Validation of a mouse conductance system to determine LV volume: comparison to echocardiography and crystals. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(4), H1698-1707.
199. Drummond, A. H.; Beckett, P.; Brown, P. D.; Bone, E. A.; Davidson, A. H.; Galloway, W. A.; Gearing, A. J.; Huxley, P.; Laber, D.; McCourt, M.; Whittaker, M.; Wood, L. M.; Wright, A. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. NY. Acad. Sci., 1999, 878, 228-235.
200. Brower, G. L.; Levick, S. P.; Janicki, J. S. Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am. J. Physiol. Heart Circ. Physiol., 2007, 292(6), H3057-3064.
201. Klotz, S.; Danser, A. H.; Foronjy, R. F.; Oz, M. C.; Wang, J.; Mancini, D.; D'Armiento, J.; Burkhoff, D. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J. Am. Coll. Cardiol., 2007, 49(11), 1166-1174.
202. Cimmino, G.; Ibanez, B.; Giannarelli, C.; Prat-Gonzalez, S.; Hutter, R.; Garcia, M.; Sanz, J.; Fuster, V.; Badimon, J. J. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. Int. J. Cardiol., 2010.
203. Andreou, I.; Tousoulis, D.; Miliou, A.; Tentolouris, C.; Zisimos, K.; Gounari, P.; Siasos, G.; Papageorgiou, N.; Papadimitriou, C. A.; Dimopoulos, M. A.; Stefanadis, C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis, 2010, 210(1), 194-198.
204. Tousoulis, D.; Andreou, I.; Tentolouris, C.; Antoniades, C.; Papageorgiou, N.; Gounari, P.; Kotrogiannis, I.; Miliou, A.; Charakida, M.; Trikas, A.; Stefanadis, C. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int. J. Cardiol., 2010, 145(3), 438-443.
205. Hessel, M. H.; Bleeker, G. B.; Bax, J. J.; Henneman, M. M.; den Adel, B.; Klok, M.; Schalij, M. J.; Atsma, D. E.; van der Laarse, A. Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels. Eur. J. Heart Fail., 2007, 9(10), 1058-1063.
206. Rastogi, S.; Gupta, R. C.; Mishra, S.; Morita, H.; Tanhehco, E. J.; Sabbah, H. N. Long-term therapy with the acorn cardiac support device normalizes gene expression of growth factors and gelatinases in dogs with heart failure. J. Heart Lung. Transplant, 2005, 24(10), 1619-1625.
207. Rastogi, S.; Mishra, S.; Zaca, V.; Mika, Y.; Rousso, B.; Sabbah, H. N. Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiology, 2008, 110(4), 230-237.
208. Chen, K.; Li, D.; Zhang, X.; Hermonat, P. L.; Mehta, J. L. Anoxiareoxygenation stimulates collagen type-I and MMP-1 expression in cardiac fibroblasts: modulation by the PPAR-gamma ligand pioglitazone. J. Cardiovasc. Pharmacol., 2004, 44(6), 682-687.
209. Voloshenyuk, T. G.; Gardner, J. D. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 299(2), R683-693.